Biotech Co.* |
Pharma Co. |
Type/Product Area | Terms/Details (Date) |
| | |||
Affibody AB* |
Agilent Technologies Inc. |
Deal to develop advanced protein sample preparation solutions for biomarker discovery |
Affibody will design and develop engineered Affibody ligands for specific protein targets designated by Agilent; terms of the deal were not disclosed (8/23) |
| |||
Affymetrix |
GlaxoSmithKline plc (UK) |
GSK got rights to use the Affymetrix GeneChip Human Mapping 500K Array Set to find genetic variations |
GSK will use the arrays to perform whole- genome association studies across tens of thousands of samples; terms of the deal were not disclosed (10/4) |
| |||
Agensys Inc.* |
Merck & Co. Inc. |
Deal to develop and sell Agensys' AGS-PSCA, a fully human monoclonal antibody to prostate stem cell antigen; Merck also got rights to the PSCA target and to any resulting products |
Agensys gets $17.5M up front and up to $11.5M more over 12 months; successful development of AGS-PSCA would trigger milestone payments of $95M, and more than $170M if multiple oncology indications are developed; Agensys also would get royalties on sales (10/17) |
| |||
Agensys Inc.* |
Sanofi-Aventis Group (France) |
Collaboration with Sanofi Pasteur to develop vaccines against colorectal and prostate cancers |
Sanofi gets an option to license up to six targets for development in the three-year deal; Agensys gets an up-front payment, research funding and progress payments; it also could receive license fees, milestone payments and royalties on resulting sales (10/10) |
| |||
Alligator |
Undisclosed European company |
Deal to optimize an undisclosed protein using Alligator's FIND technology |
Alligator is entitled to milestone payments in the deal (10/17) |
| |||
Alnylam |
Novartis AG (Switzerland) |
Multiyear collaboration to discover therapeutics based on RNA interference; Alnylam retains rights to its own pipeline and has certain profit- sharing options |
Novartis paid $58.5M up front for the purchase of 5.3M Alnylam shares at $11.11 each, representing 19.9% of the company; Alnylam will get another $10M up front and could receive a total of $700M if multiple products are developed, plus royalties on resulting sales (9/7) |
| |||
Astex |
Boehringer Ingelheim GmbH (Germany) |
Collaboration to discover, develop andmarket drug candidates against undisclosed disease targets |
Astex will provide candidates to BI; it gets up-front and research payments, along with potential milestone and royalty payments (8/31) |
| |||
Avalon |
Novartis AG (Switzerland) |
Collaboration to discover small- molecule compounds against a pathway selected by Novartis |
Avalon is entitled to an up-front payment, research support and milestone payments (9/13) |
| |||
Bio-Medisinsk |
GlaxoSmithKline plc (UK) |
Collaboration covering the 5-HT4 receptor antagonist piboserod (SB 207266) |
BMI will complete Phase II testing; GSK then has an option to take over development and marketing in heart failure in exchange for a license fee, milestone payments and royalties on any sales (9/19) |
| |||
BioSante |
Unnamed European company |
Option deal to use BioSante's calcium phosphate nanotechnology in the development of a series of allergy products |
BioSante gets $0.25M up front; if a license agreement results, it would get license fees, annual maintenance payments and potential milestone and royalty payments (9/14) |
| |||
BioSyntech |
Kuhnil Pharma Co. Ltd. (South Korea) |
Kuhnil got exclusive rights in Korea to BioSyntech's BST- CarGel and BST- nPod products |
Kuhnil purchased 1.5M shares for $1.2M; further details on the letter of intent were not disclosed (10/18) |
| |||
BioVisioN AG* |
Abbott Laboratories |
Collaboration on research to discover novel biomarkers for lung cancer |
BioVisioN will analyze biological samples provided by Abbott; it will get research payments and could get milestone and royalty payments (9/9) |
| |||
Celera |
Merck & Co. Inc. |
They extended their deal to develop treatments for Alzheimer's disease |
Celera will genotype gene-based mutations in sample collections as part of an effort to discover targets and biomarkers; terms were not disclosed (9/7) |
| |||
CeMines Inc.* |
Colorado Heart & Body Imaging LLC |
CHBI got rights to use technology from CeMines in upcoming clinical studies |
CeMines' CellCorrect LAb Detection Test Kits will be used in a program to detect lung cancer (9/13) |
| |||
Cerenis |
Nippon Chemiphar Co. Ltd. (Japan) |
Deal to develop small-molecule therapies based on PPAR (peroxisome proliferator activated receptor) delta agonists |
Cerenis gets access to PPAR delta agonists for developing HDL therapies to help reduce cholesterol buildup; Nippon gets up to $30M in milestone payments and royalties on any sales; it also gets rights in Asia; Cerenis has rights elsewhere (8/30) |
| |||
ChemDiv Inc.* |
Schering AG (Germany) |
ChemDiv will use its small- molecule chemistry expertise to support Schering programs |
The medicinal chemistry research deal will run at least two years; terms were not disclosed (9/14) |
| |||
Chromos |
Becton Dickinson and Co. |
BD got rights to patents related to expansion of antigen-specific T cells for a limited field of use |
Chromos get license and maintenance fees and is eligible for milestone and royalty payments; the field of use was not disclosed (10/5) |
| |||
Collegium |
BTG plc (UK) |
Collaboration to develop CP-141, a new formulation of a product used to treat asthma |
They will co-fund the development program and share any resulting revenues (8/31) |
| |||
Curis Inc. |
Procter & Gamble Pharmaceuticals |
Deal to evaluate and develop treatments for hair growth regulation using Curis' Hedgehog agonist technology |
Curis gets $0.5M up front and up to $2.8M in preclinical milestones, as well as royalties on any sales; milestone payments could exceed $100M if a product is marketed; Curis retains certain co- development options and rights in certain fields (9/19) |
| |||
Cytomedix |
COBE Cardiovascular Inc. (unit of the Sorin Group; Italy) |
COBE licensed all rights to the "Knighton" patent of autologous platelet releasate therapies for healing purposes |
Cytomedix gets an up-front royalty payment and is entitled to royalties of 7.5% and 1.5% on sales of disposable products and hardware products, respectively (10/10) |
| |||
Epitome |
EMD Biosciences (unit of Merck KGaA; Germany) |
Deal under which Epitome will develop reagents to measure intracellular signaling proteins |
Epitome will get a technology access fee, and could receive development payments and royalties on product sales (9/14) |
| |||
Epitomics |
Hoffmann-La Roche Inc. |
Roche licensed rabbit monoclonal antibody technology, for use in discovery and development of antibodies for cancer and other diseases |
Epitomics is entitled to milestone payments and royalties on sales of products developed from the RabMab technology (10/18) |
| |||
EvoGenix Ltd. |
GlaxoSmithKline plc (UK) |
Deal to apply EvoGenix's EvoGene technology to compounds in GSK's pipeline |
EvoGenix gets research funding for up to three projects and is eligible to receive milestone and royalty payments on resulting products (10/6) |
| |||
ExonHit |
BioMerieux SA (France) |
They extended for six years a deal to develop blood diagnostics in the area of early cancer detection |
ExonHit gets R&D funding for each cancer studied; there will be at least five research programs; ExonHit also is entitled to milestone and royalty payments on resulting products (10/13) |
| |||
Genaissance |
Otsuka Pharmaceutical Co. Ltd. (Japan) |
Genaissance will apply its HAP Technology in order to identify genetic markers related to drug response |
The companies will co-own technology coming from the pharmacogenomic effort, and both would be entitled to royalties on resulting diagnostic products (9/21) |
| |||
Genaissance |
Sankyo Co. Ltd. (Japan) |
Genaissance will apply it HAP Technology to discover genetic markers of drug response for Sankyo |
Genaissance will receive license and other fees from Sankyo and has certain rights to share ownership of companion genetic tests (10/3) |
| |||
Gene Logic |
Pfizer Inc. |
Gene Logic will seek new therapeutic indications for a number of Pfizer drug candidates not currently in active development |
Gene Logic is entitled to milestone payments on each compound and royalties on sales of any resulting drugs (9/27) |
| |||
Gen-Probe Inc. |
Millipore Corp. |
Deal to exclusively develop and sell nucleic acid testing products for microbiological and virus monitoring |
Gen-Probe primarily will be responsible for assay development and manufacturing, while Millipore will manage commercialization (8/31) |
| |||
GlycoFi Inc.* |
Eli Lilly and Co. |
Collaboration to discover and develop antibodies and other therapeutic proteins using GlycoFi's protein optimization technology | They will initiate 10 protein optimization programs over the extendable two-year research term; GlycoFi gets an up-front pay- ment, an equity investment and is entitled to milestone and royalty payments on resulting products (10/03) |
| |||
HistoRx Inc.* |
Eli Lilly and Co. |
Collaboration to apply the HistoRx AQUA platform for quantitative pathology analysis |
The goal is to develop proteomic information to elucidate pathway data; terms of the deal were not disclosed (10/13) |
| |||
Illumina Inc. |
GlaxoSmithKlineplc(UK) |
Illumina will conduct genetic studies for thousands of GSK samples covering multiple projects |
Terms of the multiyear genotyping services |
| |||
Immunetrics |
Eli Lilly and Co. |
Deal to apply in silico modeling technology to clinical trial design |
Immunetrics will apply the technology to an undisclosed project at Lilly; terms were not disclosed (9/7) |
| |||
ImmunoGen |
Sanofi-Aventis Group (France) |
Sanofi exercised its right to extend their collaboration focused on antibody-based anticancer products |
ImmunoGen will get $18.2M in research support over the 12 months beginning Sept. 1, 2006; ImmunoGen remains entitled to milestone and royalty payments from the 2003 deal (8/31) |
| |||
InforSense |
Bayer Healthcare AG(Germany) |
Bayer will use InforSense technology to enhance its drug discovery informatics infrastructure |
Terms of the deal were not disclosed (9/8) |
| |||
Innocoll Inc.* |
Medexis SA (Greece; part of the Gerolymatos Group of Companies) |
Deal to develop a wound- healing product based on Innocoll's CollaRx membrane technology |
Medexis will fund development and be responsible for regulatory applications; terms of the deal were not disclosed (9/8) |
| |||
Inpharmatica |
Schering AG (Germany) |
Collaboration to prioritize proteins as drug targets |
Schering got rights to use Inpharmatica's Biopendium and Chematica technologies; terms were not disclosed (10/17) |
| |||
Ipsogen SAS* |
Two pharmaceutical companies |
Collaborations focused on identifying biomarkers that may drive the response to anticancer drugs |
Ipsogen will collect samples from clinical trials and will perform sample processing and pathology analysis, while Genaissance will perform genotyping and data analysis for the undisclosed partners (9/12) |
| |||
Isotechnika |
Atrium Medical Corp. |
Exclusive deal to develop Isotechnika's TAFA93 and ISA247 with drug-eluting devices in various indications |
Isotechnika gets $3M up front and is entitled to milestone and royalty payments on resulting products; Atrium will fund development (9/30) |
| |||
Lipoxen |
Baxter Healthcare Corp. |
Lipoxen will apply its technology to develop blood-clotting factors with extended biological activity |
Lipoxen gets research funding along with potential milestone and royalty payments (9/27) |
| |||
Lipoxen |
National Biotechnologies OAO (Russia) |
National Biotechnologies got certain rights to extended-release insulin and interferon products |
Lipoxen gets $750,000 up front and is entitled to royalty payments; the license covers Russia, Ukraine and Kazakhstan (9/27) |
| |||
MedImmune |
GlaxoSmithKline plc (UK) |
MedImmune got rights to certain anti- staphylococcal monoclonal antibodies,including the Phase II product BSYX-A110 |
GSK gets an up-front payment as well as potential milestone payments and royalties on sales; MedImmune also assumed responsibility for any milestone and royalty payment obligations to Biosynexus (8/29) |
| |||
MerLion |
Astellas Pharma Inc. (Japan) |
Deal to discover and develop drugs derived from natural products chemistry |
MerLion will identify chemical seeds from targets provide by Astellas; MerLion would be entitled to milestone and royalty payments on resulting compounds (10/4) |
| |||
Mesoblast Ltd. |
Unnamed medical device company |
The device company will provide carrier materials to Mesoblast |
The materials will be used in combination with Mesoblast's adult stem cells in pre-clinical trials (8/24) |
| |||
MorphoSys |
Centocor Inc. (unit of Johnson & Johnson) |
MorphoSys will generate antibodies to a target molecule discovered in their collaboration |
MorphoSys is entitled to licensing fees and milestone and royalty payments (9/6) |
| |||
MorphoSys |
Eli Lilly and Co. |
Cross-licensing deal covering the use of certain recombinant protein technologies |
MorphoSys is entitled to licensing fees and milestone and royalty payments on covered products developed by Lilly; the deal settled patent litigation (9/23) |
| |||
MorphoSys |
Schering AG (Germany) |
They added three programs to existing collaboration, and Schering got eight licenses for in vivo diagnostic applications |
The three added programs cover antibody development; MorphoSys is entitled to license payments (10/10) |
| |||
MorphoSys |
Shionogi & Co. Ltd.(Japan) |
Shionogi licensed access to the HuCAL GOLD antibody library for use in drug discovery programs |
MorphoSys gets an up-front payment and annual user fees under terms of the three-year deal (9/7) |
| |||
Nektar |
Baxter Healthcare Corp. |
Deal to develop PEGylated forms of blood-clotting proteins for treating hemophilia |
Nektar is entitled to research payments along with potential milestone payments, manufacturing revenues and sales royalties (9/29) |
| |||
NexMed Inc. |
Novartis International Pharmaceutical Ltd. |
Novartis got worldwide rights to NexMed's Phase I product NM100060, a lacquer treatment for nail fungus |
NexMed gets $4M up front and up to $47M in milestone payments, as well as royalties on any resulting sales (9/15) |
| |||
NicOx SA |
Grupo Ferrer Internacional SA (Spain) |
They expanded deal to discover and develop nitric oxide- donating corticosteroids for dermatology applications |
Ferrer got an option to acquire U.S. rights; NicOx is eligible to receive more milestone and royalty payments than called for in the original deal (9/15) |
| |||
Nobex Corp.* |
Biocon Ltd. (India) |
Agreement to co-develop an oral brain- ype natriuretic peptide product for treating cardiovascular disease |
They will use the oral peptide delivery technology of Nobex with the peptide production capabilities of Biocon; terms of the deal were not disclosed (8/23) |
| |||
Novavax |
Esprit Pharma Inc. |
Esprit is getting rights to market Estrasorb (estradiol topical emulsion) in North America |
Novavax will get $12.5M within one year, as well as royalties on sales and milestone payments if certain sales levels are reached (10/18) |
| |||
Oxford Genome |
UCB Group SA (Belgium) |
UCB licensed rights to OGS' OGAP database |
The database is used to discover and validate targets and biomarkers; terms of the deal were not disclosed (10/18) |
| |||
Perlegen |
GlaxoSmithKline plc (UK) |
New deal enables multiple genetics- related studies to be conducted over a period of time |
It is the third deal between the companies; terms were not disclosed (8/31) |
| |||
Perlegen |
Merck & Co. Inc. |
Deal to perform a high-density whole-genome analysis of more than 1,000 individuals |
Perlegen will assay genetic variations in DNA samples provided by Merck; terms of the deal were not disclosed (10/04) |
| |||
Pharmacopeia |
NV Organon (the Netherlands) |
They extended drug-discovery collaboration from 2002 until 2007 |
Organon elected to continue the deal by accepting the latest preclinical lead candidate generated by Pharmacopeia; specific terms were not disclosed (8/30) |
| |||
Plureon Corp.* |
Becton Dickinson and Co. |
Deal for diabetes research and development using Plureon's stem cell technology |
BD will sponsor Plureon research for up to three years and be responsible for further development; further terms were not disclosed (10/14) |
| |||
Primagen |
Focus Diagnostics Inc. |
Focus got rights to develop PCR detection for human coronavirus NL63 |
Terms of the license deal were not disclosed (9/12) |
| |||
Prolexys |
GlaxoSmithKline plc (UK) |
GSK got nonexclusive rights to the Prolexys Human Interactome Database |
The database contains more than 258,000 human protein- rotein interactions; terms of the deal were not disclosed (10/3) |
| |||
Revivicor Inc.* |
Zimmer Holdings Inc. |
Zimmer acquired worldwide rights to genetically engineered xenogeneic tissues for regenerative therapies |
Zimmer initially plans to develop the technologies for orthopedic applications; terms of the deal were not disclosed (9/20) |
| |||
Sangamo |
LifeScan Inc. (unit of Johnson & Johnson) |
They expanded deal to use Sangamo's zinc finger DNA- binding proteins to develop therapeutic cell lines for treating diabetes |
Sangamo will receive expanded research funding from LifeScan through 2006 under the second expansion of the deal (9/14) |
| |||
Sangamo |
Novo Nordisk A/S (Denmark) |
Novo got access to Sangamo's zinc finger DNA-binding protein technology |
Novo will evaluate the technology for use in enhancing protein production; terms of the deal were not disclosed (9/7) |
| |||
Scil Technology |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Scil acquired worldwide rights to the growth factor MIA/CD- RAP from Roche Diagnostics |
Roche licensed back rights to CD-RAP for use in research diagnostics; terms of the deal were not disclosed (10/10) |
| |||
Scynexis Inc.* |
Teijin Pharma Ltd. (Japan) |
Scynexis will provide medicinal and analytical chemistry services for Teijin research programs |
Terms of the deal were not disclosed (10/13) |
| |||
Sirna |
Allergan Inc. |
Deat to develop Sirna-027, a Phase I product for age-related macular degeneration, and other RNAi-based drugs for ophthalmic diseases |
Sirna gets $5M up front and is eligible for development milestones of up to $245M in addition to research funding and royalties on any resulting sales; Sirna also can get manufacturing revenues (9/29) |
| |||
Sonus |
Schering AG (Germany) |
Schering got worldwide rights to Sonus' Tocosol Paclitaxel, a cancer product in Phase III trials |
Schering made a $15M equity investment, buying 3.9M shares; Sonus also got an up-front license fee of $20M, and could get regulatory milestone payments of up to $132M, as well as sales royalties and sales milestones (10/18) |
| |||
Strand Life |
Elan Corp. plc (Ireland) |
Strand will use its in silico technologies to support Elan drug discovery efforts |
Terms of the deal were not disclosed (9/29) |
| |||
TNO Pharma* |
Mitsubishi Pharma Corp. (Japan) |
Collaboration to further characterize a set of disease targets from Mitsubishi |
TNO will use its siRNA-based knockdown technology and disease models in the deal, terms of which were not disclosed (9/6) |
| |||
Tm Bioscience |
Abbott Laboratories |
Nonexclusive license deal covering certain technology in human and pathogen genotyping and other areas |
The license covers Tm's current and future products in all fields of use; further details were not disclosed (10/3) |
| |||
TorreyPines |
Eisai Co. Ltd. (Japan) |
Collaboration to discover genes responsible for late- onset Alzheimer's disease |
The deal continues Eisai's support for the program that began in 2001; TorreyPines gets a signing fee and research support; Eisai gets first negotiation rights on any resulting gene targets (10/11) |
| |||
Tripos Inc. |
Servier (France) |
Collaboration to further design and synthesize compounds for potential drug development |
Tripos will apply its chemistry technologies in the deal, terms of which were not disclosed (8/30) |
| |||
Vical Inc. |
Merck & Co. Inc. |
Merck got options to use Vical's nonviral gene delivery technology for additional cancer targets |
In exchange, Vical got nonexclusive rights to use the technology for vaccines against HIV; also, Merck got an option to use electroporation-enhanced delivery technology with HIV vaccines (9/12) |
| |||
XOMA Ltd. |
Wyeth |
Wyeth got a nonexclusive license to XOMA's expression technology |
Wyeth will use the technology to develop and produce recombinant proteins; terms of the deal were not disclosed (9/7) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
@ News occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; TSE: Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.